A trial looking at pertuzumab for prostate cancer (BO17004)

Cancer type:

Prostate cancer




Phase 2

This trial looked at pertuzumab (also called Omnitarg) for prostate cancer that was no longer responding to hormone therapy.

Doctors often use hormone therapy to treat prostate cancer. But usually at some point, prostate cancer becomes resistant Open a glossary item to hormone therapy and continues to grow. This can happen after months or even years of treatment. You may hear this called ‘hormone refractory’ prostate cancer.

Pertuzumab is a monoclonal antibody. Monoclonal antibodies are a type of biological therapy. They look for specific proteins on the surface of cells. Pertuzumab looks for a protein called HER2, which is made by some prostate cancers.

Doctors hoped that pertuzumab would be useful for treating hormone refractory prostate cancer. The aims of this trial were to

  • See how well pertuzumab worked
  • Find the best dose to give
  • Learn more about the side effects

Summary of results

The trial team found that pertuzumab did not help men with hormone refractory prostate cancer.

The doctors measured the level of PSA Open a glossary item in the men’s blood to see if the cancer was responding to treatment. When cancer cells are killed off by treatment, your PSA reading goes down.

The trial recruited 68 men. They all had pertuzumab every 3 weeks for up to 24 weeks. The researchers looked at 2 different doses.

  • The level of PSA did not go down in any of the men
  • In 22 men, the PSA level stayed the same
  • In 45 men, the PSA level went up or scans showed that the cancer had got bigger
  • The trial team did not have results for one man

Side effects included diarrhoea, fatigue and nausea. There were more serious side effects in 5 men, including changes to the heart.

As none of the men taking part had a drop in their PSA level, the trial was stopped.

We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (peer reviewed Open a glossary item) and published in a medical journal. The figures we quote above were provided by the trial team. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Prof M Mason
Dr J Graham
Prof J de Bono

Supported by


Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 292

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Keith took part in a trial looking into hormone therapy

A picture of Keith

"Health wise I am feeling great. I am a big supporter of trials - it allows new treatments and drugs to be brought in.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page